Platform trials for efficient treatment discovery in myotonic dystrophy type 1

Abstract Background Myotonic dystrophy type 1 is an autosomal dominant disorder that leads to progressive weakness, myotonia, and multisystemic disease burden. The primary pathogenic event, a toxic CUG repeat expansion, is potentially treatable with precision genetic therapeutics. As a result, multiple potential disease modifying therapies have advanced to clinical trials. However, standalone single therapy trials may compete for participants and sites, slowing advancement. Here we explore a potential platform trial design. Methods The overall platform designs selected were based on similar designs in other neurodegenerative disorders. The authors utilized a large natural history dataset, END-DM1, to explore potential primary endpoints. Using the 10-meter walk/run time as an example, the authors compared an idealized no-competition standalone benchmark; 3, 5, and 8 concurrently recruiting standalone trials; and a platform trial with three concurrent regimens and shared concurrent controls. The primary comparison is between the platform and competing trials. The primary simulations assumed that 10% of trials/regimens were effective with an effect of 0.6 standard deviations, while the ineffective 90% of trials/regimens had no effect. Competing approaches compared multiple metrics, including time to the first positive result, participant use, regimen-level type-I error and power, and program-level false-positive rates. Results The fully utilized three-regimen platform with N = 80 per regimen and shared controls preserved power compared to standalone trials and reduced the overall duration and participant usage of the clinical trial. With an annual pool of 150 participants, the mean time to first positive result was 6.1 years for the fully utilized platform, compared with 8.8 and 9.7 years for the three and five competing standalone trials. Mean enrollment was 921.7 participants for the fully utilized platform and 1,320.2 and 1,458.2 participants for the three and five competing standalone trials. Conclusions Platform clinical trial designs may increase the efficiencies of therapeutic trials, particularly when there are multiple competing therapeutic trials. In myotonic dystrophy type 1, where multiple therapeutics have the potential to address the genetic defect, platform trials may promote the rapid access of therapies to clinicians and patients.

Authors

Publication Details

Journal
Orphanet Journal of Rare Diseases
Published
2026-11-14
DOI
https://doi.org/10.1186/s13023-026-04725-4
Primary Topic
Statistical Methods in Clinical Trials
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Platform trials for efficient treatment discovery in myotonic dystrophy type 1

Nicholas Elwood Johnson, Melanie Quintana, Sansone, Sub Subramony et al.
Orphanet Journal of Rare Diseases
Statistical Methods in Clinical Trials
article

Platform trials for efficient treatment discovery in myotonic dystrophy type 1

Nicholas Elwood Johnson, Melanie Quintana, Sansone, Sub Subramony, Benedikt Schoser, Philip White, Jeffery Statland, Lindsay Berry
article en

Abstract

Abstract Background Myotonic dystrophy type 1 is an autosomal dominant disorder that leads to progressive weakness, myotonia, and multisystemic disease burden. The primary pathogenic event, a toxic CUG repeat expansion, is potentially treatable with precision genetic therapeutics. As a result, multiple potential disease modifying therapies have advanced to clinical trials. However, standalone single therapy trials may compete for participants and sites, slowing advancement. Here we explore a potential platform trial design. Methods The overall platform designs selected were based on similar designs in other neurodegenerative disorders. The authors utilized a large natural history dataset, END-DM1, to explore potential primary endpoints. Using the 10-meter walk/run time as an example, the authors compared an idealized no-competition standalone benchmark; 3, 5, and 8 concurrently recruiting standalone trials; and a platform trial with three concurrent regimens and shared concurrent controls. The primary comparison is between the platform and competing trials. The primary simulations assumed that 10% of trials/regimens were effective with an effect of 0.6 standard deviations, while the ineffective 90% of trials/regimens had no effect. Competing approaches compared multiple metrics, including time to the first positive result, participant use, regimen-level type-I error and power, and program-level false-positive rates. Results The fully utilized three-regimen platform with N = 80 per regimen and shared controls preserved power compared to standalone trials and reduced the overall duration and participant usage of the clinical trial. With an annual pool of 150 participants, the mean time to first positive result was 6.1 years for the fully utilized platform, compared with 8.8 and 9.7 years for the three and five competing standalone trials. Mean enrollment was 921.7 participants for the fully utilized platform and 1,320.2 and 1,458.2 participants for the three and five competing standalone trials. Conclusions Platform clinical trial designs may increase the efficiencies of therapeutic trials, particularly when there are multiple competing therapeutic trials. In myotonic dystrophy type 1, where multiple therapeutics have the potential to address the genetic defect, platform trials may promote the rapid access of therapies to clinicians and patients.

Orphanet Journal of Rare Diseases
Statistical Methods in Clinical Trials
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon